Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 199

Results For "UST"

5839 News Found

Philips and Masimo partner to advance access to patient monitoring technologies
Technology | September 16, 2025

Philips and Masimo partner to advance access to patient monitoring technologies

Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions


FDA launches crackdown on deceptive drug advertising
Policy | September 16, 2025

FDA launches crackdown on deceptive drug advertising

The FDA is beginning rulemaking to close the “adequate provision” loophole


Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial
Clinical Trials | September 16, 2025

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management


Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India
News | September 16, 2025

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India

Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB


Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule
News | September 16, 2025

Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule

Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders


AstraZeneca’s Phase III FLAURA2 trial shows positive result
News | September 15, 2025

AstraZeneca’s Phase III FLAURA2 trial shows positive result

Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial


Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
Drug Approval | September 15, 2025

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis